Abilify (Aripiprazole) Dosing Guidelines
For schizophrenia in adults, start Abilify at 10-15 mg once daily; for bipolar mania, start at 15 mg daily as monotherapy or 10-15 mg as adjunctive therapy; for major depressive disorder augmentation, start at 2-5 mg daily; and for pediatric irritability in autism, start at 2 mg daily and titrate to 5-15 mg daily. 1
Schizophrenia Dosing
Adults
- Starting dose: 10 or 15 mg once daily, without regard to meals 1
- Target dose: 10-15 mg/day (doses above this are not more effective) 1
- Dose range: 10-30 mg/day is the FDA-approved range, though evidence supports 10-25 mg/day as optimal 2
- Titration: Wait at least 2 weeks before increasing dose (time to steady-state) 1
- Full effect: May take 1-4 weeks to reach maximum therapeutic benefit 3
Important caveat: While the FDA label allows up to 30 mg/day, systematic reviews show that doses above 10-15 mg/day provide no additional efficacy for most patients 1, 2. Doses below 10 mg/day are ineffective except for acute agitation 2.
Adolescents (13-17 years)
- Starting dose: 2 mg once daily 1
- Titration schedule: Increase to 5 mg after 2 days, then to target of 10 mg after 2 additional days 1
- Target dose: 10 mg/day 1
- Maximum studied: 30 mg/day showed no advantage over 10 mg/day 1
- Subsequent increases: Use 5 mg increments if needed 1
Switching from Other Antipsychotics
- Approach: Gradual cross-titration is preferred over abrupt switching 1
- Overlap period: Minimize the duration of concurrent antipsychotic administration 1
- Clinical context: Immediate discontinuation may be acceptable for some patients, but gradual transition is safer for most 1
Bipolar I Disorder (Acute Mania/Mixed Episodes)
Adults
- Monotherapy starting dose: 15 mg once daily 1
- Adjunctive therapy (with lithium/valproate): 10-15 mg once daily 1
- Target dose: 15 mg/day 1
- Maximum dose: May increase to 30 mg/day based on clinical response 1
- UK consensus guidance: Start at 15 mg/day (range 5-20 mg/day); use adjunctive medication early to manage side effects like agitation or insomnia 4
Pediatrics (10-17 years)
- Starting dose: 2 mg/day 1
- Titration: Increase to 5 mg after 2 days, then to 10 mg after 2 additional days 1
- Target dose: 10 mg/day 1
- Subsequent increases: Use 5 mg/day increments if needed 1
- Same dosing applies whether used as monotherapy or adjunctive to lithium/valproate 1
Major Depressive Disorder (Adjunctive Treatment)
Adults
- Starting dose: 2-5 mg/day (added to existing antidepressant) 1
- Dose range: 2-15 mg/day 1
- Titration: Increase by up to 5 mg/day at intervals of no less than 1 week 1
- Reassessment: Periodically evaluate continued need for treatment 1
Irritability Associated with Autistic Disorder
Pediatrics (6-17 years)
- Starting dose: 2 mg/day 1
- Initial increase: Titrate to 5 mg/day 1
- Target range: 5-15 mg/day 1
- Titration: Increase by up to 5 mg/day at intervals of no less than 1 week 1
- Reassessment: Periodically evaluate continued need for treatment 1
Dose Adjustments for Drug Interactions
CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine)
- Reduce aripiprazole dose by 50% when co-administered 1
- Rationale: Aripiprazole is metabolized by CYP2D6; inhibitors increase plasma levels 5, 6
CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)
- Reduce aripiprazole dose by 50% when co-administered 1
CYP3A4 Inducers (e.g., carbamazepine, rifampin)
- Double the aripiprazole dose when co-administered 1
- Return to original dose when inducer is discontinued 1
Combined CYP2D6 and CYP3A4 Inhibitors
- Reduce aripiprazole dose by 75% 1
Pharmacokinetic Considerations
- Half-life: Approximately 75 hours for aripiprazole and 94 hours for its active metabolite (dehydroaripiprazole) 3, 6
- Time to steady-state: 14 days for both active moieties 3, 6
- Time to peak concentration: 3-5 hours after oral administration 6
- Bioavailability: 87% 6
- CYP2D6 poor metabolizers: Consider starting at 5 mg/day, as these patients achieve higher plasma levels 5
Therapeutic Drug Monitoring
Therapeutic reference range: 120-270 ng/mL for aripiprazole alone, or 180-380 ng/mL for the active moiety (aripiprazole + dehydroaripiprazole) 5
- When to consider TDM: High interindividual variability and CYP2D6 polymorphisms make TDM particularly useful for aripiprazole 5
- Target for most patients: A starting dose of 10 mg will achieve effective concentrations in blood and brain for most patients 5
- Poor metabolizers: 5 mg may be sufficient 5
Special Populations
Elderly Patients
- Black box warning: Increased mortality risk in elderly patients with dementia-related psychosis 1
- Not approved for dementia-related psychosis 1
Renal Impairment
- No dose adjustment required 1
Hepatic Impairment
- No dose adjustment required 1
Common Pitfalls to Avoid
Don't exceed 15 mg/day in schizophrenia without clear rationale: Higher doses rarely provide additional benefit and increase side effects 1, 2
Don't rush titration: Wait the full 2 weeks for steady-state before increasing dose 1
Don't forget CYP interactions: Failure to adjust dose with strong CYP2D6/3A4 inhibitors or inducers can lead to toxicity or treatment failure 1
Don't abruptly switch antipsychotics: Gradual cross-titration minimizes risk of relapse and withdrawal symptoms 1
Don't use in dementia-related psychosis: This carries a black box warning for increased mortality 1
Monitor for akathisia early: This is one of the most common side effects and can emerge within days of initiation 4, 6
Side Effect Management
- Nausea, insomnia, agitation: Typically resolve within days; consider adjunctive short-term medication if severe 4
- Akathisia: May require dose reduction or addition of beta-blocker/benzodiazepine 6
- Weight gain: Less problematic than with olanzapine or clozapine, but monitor metabolic parameters 7, 8